HP (High Potency) APIs Market Technological Challenges, Market Update, Volume Analysis, Growth Prospects And Forecast 2023-2032|Eli Lily and Company, Novartis AG, Bristol-Myers Squibb Company, Roche Diagnostics Ltd., Sanofi, Hospira Inc.

Spread the love

The HP (High Potency) APIs Global Market Report 2023 by The Business Research Company, provides HP (high potency) APIs market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten-year historic period – 2010-2021, and a ten-year forecast period – 2023-2032.

Learn More On The HP (High Potency) APIs Market:

https://www.thebusinessresearchcompany.com/report/hp-high-potency-api-global-market-report

According to The Business Research Company’s HP (High Potency) APIs Global Market Report 2023, the market size grew from $24.53 billion in 2022 to $26.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global high potency APIs is expected to grow from $36.14 billion in 2027 at a CAGR of 7.9%.

The rising number of cancer cases coupled with increasing sales of cancer drugs contributed to the growth of the HP (high potency) APIs market. The rising incidence of cancer is resulting in increasing R&D for anticancer drugs which in turn is propelling the demand for the market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=2814&type=smp

The HP (high potency) APIs market is segmented:

1) By Type: Innovative HPAPI, Generic HPAPI

2) By Synthesis Type: Synthetic HPAPI, Biotech HPAPI

3) By Therapeutic Application: Oncology, Hormonal Disorder, Glaucoma, Other Therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, and Erectile Dysfunction)

The companies dealing in the HP (high potency) APIs market are focusing on strategies such as production facility expansion and mergers and acquisitions to maintain their position in the competitive business environment. For instance, in June 2022, MilliporeSigma, a US-based global life science business, opened the doors to its $65 million facility for the production of high-potency active pharmaceutical ingredients (HPAPI), with an emphasis on cancer treatments. In January 2020, Piramal Pharma Solutions (PPS) declared expenditure of $19 million to enhance its operation in Aurora, Ontario, Canada, with an additional 975 m2 of production space in a new wing for API production, including the production of HPAPI for potent compounds down to an OEL of 1 mcg/m3.

The HP (high potency) APIs market report table of contents includes: